Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL7770372 | 0.89 | ALDH1A1 (0.42) | AHRALDH1A1SOS2KDM4EALOX15 | |
| SCHEMBL1244495 | 0.82 | KDM4E (0.61) | AHRSOS2KDM4EALOX15TSHR | |
| SCHEMBL15336497 | 0.81 | AHR (0.42) | AHRSOS2SRCCTSK | |
| SCHEMBL2956687 | 0.81 | AHR (0.49) | AHRSOS2KDM4EALOX15TSHR | |
| SCHEMBL5387510 | 0.81 | AHR (0.49) | AHRALDH1A1SOS2KDM4EALOX15 | |
| SCHEMBL17963045 | 0.81 | ALDH1A1 (0.42) | AHRALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL31098054 | 0.81 | ALDH1A1 (0.42) | AHRALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL9326696 | 0.80 | AHR (0.46) | AHRALDH1A1SOS2KDM4EALOX15 | |
| SCHEMBL3815890 | 0.80 | BRD4 (0.50) | AHRKDM4EGRM5 | |
| SCHEMBL9323548 | 0.80 | AHR (0.46) | AHRSOS2KDM4EALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119612485-A | Nitrogen-doped asphalt-based hard carbon material and preparation method and application thereof | 武汉天钠科技有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-117402193-A | Chiral oxazoline-cobalt picolinite compound and synthetic method and application thereof | 郑州大学 | 2024-01-16 | — | — | CN | claimed |
| CN-117402193-B | Chiral oxazoline-pyridine-cobalt imine compound, and synthetic method and application thereof | 郑州大学 | 2026-01-30 | — | — | CN | disclosed |
| CN-119612485-A | Nitrogen-doped asphalt-based hard carbon material and preparation method and application thereof | 武汉天钠科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-117402193-A | Chiral oxazoline-cobalt picolinite compound and synthetic method and application thereof | 郑州大学 | 2024-01-16 | — | — | CN | disclosed |
| CN-117402193-A | Chiral oxazoline-cobalt picolinite compound and synthetic method and application thereof | 郑州大学 | 2024-01-16 | — | — | CN | disclosed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023027948-A1 | JAK2 INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| EP-4103558-A1 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-107849013-B | Cyanopyrrolidines as DUB inhibitors for the treatment of cancer | 特殊治疗有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-5376685-A | Arylhydrazones using as SAMDC inhibitors | CIBA-GEIGY CORPORATION (US) | 1994-12-27 | — | — | US | disclosed |
| US-5350696-A | 2-acetyl-6-cyanopyridines and their use as intermediates in the synthesis of oligo-2,6-pyridines | STERLING WINTHROP, INC. (US) | 1994-09-27 | — | — | US | disclosed |
| US-5350696-A | 2-acetyl-6-cyanopyridines and their use as intermediates in the synthesis of oligo-2,6-pyridines | STERLING WINTHROP, INC. (US) | 1994-09-27 | — | — | US | disclosed |
| US-5350696-A | 2-acetyl-6-cyanopyridines and their use as intermediates in the synthesis of oligo-2,6-pyridines | STERLING WINTHROP, INC. (US) | 1994-09-27 | — | — | US | disclosed |
| US-5238941-A | S-adenosylmethionine decarboxylase inhibitors | CIBA-GEIGY CORPORATION (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0335832-B1 | ARYL HYDRAZONES | CIBA-GEIGY AG (CH) | 1993-02-10 | — | — | EP | disclosed |
| US-5118709-A | Decarboxylase enzyme inhibitors; antitumor agents | CIBA-GEIGY CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
| US-4971986-A | ANTITUMOR AGENTS | CIBA-GEIGY CORPORATION (US) | 1990-11-20 | — | — | US | disclosed |
| EP-0335832-A2 | Aryl hydrazones | CIBA-GEIGY AG (CH) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | AHR 4159/4885ALDH1A1 3191/4885SOS2 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.